The COVID-19 pandemic, which has been a biological crisis of unprecedented nature, has altered the very nature and dynamics of the healthcare industry. The Zacks
Medical - Dental Supplies industry bore the brunt of the closure of dental practices and lower patient visits due to the COVID-19 crisis. However, recovery in dental markets has been picking up pace, primarily owing to the lifting of stay-at-home orders, rising dependence on Artificial Intelligence (AI) & Robotics and teledentistry and increase in number of patient visits. In fact, several companies have been exhibting signs of recovery despite the resurgence in cases. Industry participants like McKesson Corporation ( MCK Quick Quote MCK - Free Report) , West Pharmaceutical Services Inc. ( WST Quick Quote WST - Free Report) and Cardinal Health Inc. ( CAH Quick Quote CAH - Free Report) are likely to gain from the prospects. Industry Description
This industry primarily comprises designers, developers, manufacturers and marketers of dental consumables, dental laboratory products and dental specialty items. Some of the industry participants also provide practice management and clinical software, patient education systems, and office forms and stationery. Some key players in this space include
Becton Dickinson and Company ( BDX Quick Quote BDX - Free Report) , Patterson Companies, Inc. ( PDCO Quick Quote PDCO - Free Report) , Cooper Companies ( COO Quick Quote COO - Free Report) , Laboratory Corporation of America Holdings ( LH Quick Quote LH - Free Report) , Henry Schein, Inc. ( HSIC Quick Quote HSIC - Free Report) and AmerisourceBergen Corporation ( ABC Quick Quote ABC - Free Report) . Major Trends Shaping the Future of Medical Dental Supplies Industry : Following the COVID-19 outbreak, most of the dental practices were unable to offer routine services in the office. Teledentistry, which is a provision to offer dental services through interactive video, audio or other electronic media to provide consultation, diagnosis and treatment, helped clinicians and patients amid this crisis. In order to enhance patient care, dependence on teledentistry will continue to increase during the pandemic and beyond. For instance, Rising Dependence on Teledentistry Align Technology ( ALGN Quick Quote ALGN - Free Report) recently invested in a number of teledentistry solutions in a bid to make remote check-ups a reality. The launch of digital solutions — Invisalign Virtual Appointment and Invisalign Virtual Care — that enable dental professionals to conduct video consultations with existing Invisalign patients reflect the company’s commitment toward enhancing treatment efficiency. Such initiatives position the company well amid the crisis. : The latest technologies help dentists in carrying out minimally-invasive procedures that ensure precision and efficiency, thereby reducing patients’ trauma. The industry players actively promote digital workflows for general dentistry and dental specialties. Further, dental 3D printers are revolutionizing dentistry. These reduce time and cost through efficient utilization of orthodontics and dental practices. In fact, dental 3D printers became mainstream in 2020. For instance, Digital Influence DENTSPLY SIRONA ( XRAY Quick Quote XRAY - Free Report) has launched a single tooth replacement solution — Azento — in the United States to transform digital-implant workflow in dental care. : AI has been shaping the dental industry for quite some time now. This decade is likely to see the rise of computing power, which has become more accessible and affordable for dental practitioners. It will transform the way dentists work and patients receive treatment, especially with the introduction of robot dentists. Robots are now able to perform minimally-invasive dental work like filling cavities and extracting teeth. A report by National Business Capital & Services suggests that AI dentistry had already become mainstream by 2019-end. AI & Robotics Zacks Industry Rank Indicates Bright Prospects
The Zacks Medical Dental Supplies industry falls within the broader Zacks
Medical sector. It carries a Zacks Industry Rank #65, which places it in the top 26% of more than 250 Zacks industries. The group’s Zacks Industry Rank, which is basically the average of the Zacks Rank of all member stocks, indicates bleak near-term prospects. Our research shows that the top 50% of the Zacks-ranked industries outperforms the bottom 50% by a factor of more than 2 to 1. Before we present a few dental supplies stocks that you may want to consider for your portfolio, let’s take a look at the industry’s recent stock-market performance and valuation picture. Industry Performance
The industry has outperformed its own sector in the past year but fell short of the Zacks S&P 500 composite in the same time frame.
Stocks in this industry have collectively gained 32% compared with the Zacks Medical sector’s rise of 12.4%. Notably, the S&P 500 rallied 41.8% in the same timeframe. One Year Price Performance Industry’s Current Valuation
On the basis of the forward 12-month price-to-earnings (P/E) ratio, which is commonly used for valuing medical stocks, the industry is currently trading at 17.75X compared with the S&P 500’s 21.96X and the sector’s 21.11.
Over the last five years, the industry has traded as high as 19.77X and as low as 13.63X, with the median being at 16.70X, as the charts below show. Price-to-Earnings Forward Twelve Months (F12M) Price-to-Earnings Forward Twelve Months (F12M) 3 Promising Dental Supplies Stocks McKesson Corporation: McKesson is a health care services and information technology company. The company’s third-quarter fiscal 2021 performance exceeded its original expectations. In fact, it raised its fiscal 2021 guidance with adjusted earnings per share projected between $16.95 and $17.25 (up from the previously guided range of $16-$16.50). Moreover, the Zacks Rank #2 (Buy) company remains committed to its multi-year strategic growth initiative update that is currently expected to generate approximately $400 million to $500 million in annual pre-tax gross savings. This will be realized substantially by the end of fiscal 2021. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. For this San Francisco, CA-based company, the Zacks Consensus Estimate for 2021 revenues indicate an improvement of 3.8%. It has a trailing four-quarter earnings surprise of 14.4%, on average. Price and Consensus: MCK West Pharmaceutical Services Inc.: West Pharmaceutical manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, Ireland, France, Other European countries, and internationally. It delivered solid fourth-quarter 2020 performance, wherein its base business exhibited robust organic sales growth. The company also witnessed an advancement in COVID-19 related sales of high-value product components utilized in both therapeutics and vaccines. Solid revenue performance, especially in its biologics and generics market units and Contract Manufacturing, contributed to both the bottom and top lines. For this Exton, PA-based Zacks Rank #2 company, the Zacks Consensus Estimate for 2021 revenues suggest growth of 18.7%. It has a trailing four-quarter earnings surprise of 23.2%, on average. Price and Consensus: WST Cardinal Health, Inc.: Cardinal Health is a nation-wide drug distributor and provider of services to pharmacies, healthcare providers and manufacturers. The company’s Pharmaceutical segment is the second largest pharmaceutical distributor in the United States. The segment's products and services comprise pharmaceutical distribution, manufacturer and specialty services, and nuclear and pharmacy services, which are expected to drive the quarters ahead. Moreover, Cardinal Health’s Medical and Pharmaceutical offerings provide the company with a competitive edge in the niche space. The company remains focused on evolving growth areas with investments and partnerships in Specialty, at Home and Services. The company carries a Zacks Rank of 3 (Hold). For this Dublin, OH-based company, the Zacks Consensus Estimate for fiscal 2021 revenues suggests growth of 5.1%. It has a trailing four-quarter earnings surprise of 20%, on average. Price and Consensus: CAH